Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carrie K Jones

Showing results (11-20 of 157) with videos related to

Pageof 16
Sort By:
Trends in Pharmacological Sciences|December 9, 2008
Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophreniaP Jeffrey Conn, Craig W Lindsley, Carrie K Jones
Discovery Medicine|January 1, 2013
Emerging approaches for treatment of schizophrenia: modulation of cholinergic signalingDaniel J Foster, Carrie K Jones, P Jeffrey Conn
Handbook of Experimental Pharmacology|January 7, 2012
Muscarinic receptor pharmacology and circuitry for the modulation of cognitionMichael Bubser, Nellie Byun, Michael R Wood, et al.
Advances in Pharmacology (San Diego, Calif.)|August 6, 2019
Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disordersLaura B Teal, Robert W Gould, Andrew S Felts, et al.
Neuropharmacology|October 19, 2006
Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibitionCarrie K Jones, Brian J Eastwood, Anne B Need, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 27, 2023
M<sub>1</sub>-selective muscarinic allosteric modulation enhances cognitive flexibility and effective salience in nonhuman primatesSeyed A Hassani, Adam Neumann, Jason Russell, et al.
Advances in Neurobiology|March 17, 2023
The Evolving Role of Animal Models in the Discovery and Development of Novel Treatments for Psychiatric DisordersLaura B Teal, Shalonda M Ingram, Michael Bubser, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 3, 2011
Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's diseaseZixiu Xiang, Analisa D Thompson, Carrie K Jones, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 3, 2004
Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in ratsCarrie K Jones, Elizabeth Lutz Eberle, David B Shaw, et al.
ACS Chemical Neuroscience|January 19, 2023
M<sub>1</sub>/M<sub>4</sub>-Preferring Muscarinic Cholinergic Receptor Agonist Xanomeline Reverses Wake and Arousal Deficits in Nonpathologically Aged MiceJason K Russell, Shalonda M Ingram, Laura B Teal, et al.
Pageof 16

Showing results (11-20 of 157) with videos related to

Sort By:
Pageof 16
Trends in Pharmacological Sciences|December 9, 2008
Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophreniaP Jeffrey Conn, Craig W Lindsley, Carrie K Jones
Discovery Medicine|January 1, 2013
Emerging approaches for treatment of schizophrenia: modulation of cholinergic signalingDaniel J Foster, Carrie K Jones, P Jeffrey Conn
Handbook of Experimental Pharmacology|January 7, 2012
Muscarinic receptor pharmacology and circuitry for the modulation of cognitionMichael Bubser, Nellie Byun, Michael R Wood, et al.
Advances in Pharmacology (San Diego, Calif.)|August 6, 2019
Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disordersLaura B Teal, Robert W Gould, Andrew S Felts, et al.
Neuropharmacology|October 19, 2006
Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibitionCarrie K Jones, Brian J Eastwood, Anne B Need, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 27, 2023
M<sub>1</sub>-selective muscarinic allosteric modulation enhances cognitive flexibility and effective salience in nonhuman primatesSeyed A Hassani, Adam Neumann, Jason Russell, et al.
Advances in Neurobiology|March 17, 2023
The Evolving Role of Animal Models in the Discovery and Development of Novel Treatments for Psychiatric DisordersLaura B Teal, Shalonda M Ingram, Michael Bubser, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 3, 2011
Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's diseaseZixiu Xiang, Analisa D Thompson, Carrie K Jones, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 3, 2004
Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in ratsCarrie K Jones, Elizabeth Lutz Eberle, David B Shaw, et al.
ACS Chemical Neuroscience|January 19, 2023
M<sub>1</sub>/M<sub>4</sub>-Preferring Muscarinic Cholinergic Receptor Agonist Xanomeline Reverses Wake and Arousal Deficits in Nonpathologically Aged MiceJason K Russell, Shalonda M Ingram, Laura B Teal, et al.
Pageof 16